Osimertinib activates a TGF-β2–dependent secretory program that drives lung adenocarcinoma progression is a research paper published in Journal of Clinical Investigation (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA236781
NCI NIH HHS
Grant: R01 CA255021
Cancer Prevention and Research Institute of Texas
Grant: RP210028
NCI NIH HHS
Grant: R50 CA265307
NCI NIH HHS
Grant: R03 CA280382
NIH Office of the Director
Grant: 5R50CA265307
NIH Office of the Director
Grant: R01CA255021-01
CPRIT
Grant: RP190682
FWCI
1.42
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords